Expression Of IL-33 And IL-6 In Serum Of Patients With Multiple Myeloma

Objective:To explore the clinical significance of the changes of serum levels of interleukin-33 and interleukin-6 in patients with multiple myeloma,and to explore their internal relationship with the occurrence and development of mm disease,and to provide theoretical basis and clinical experience for the targeted treatment of multiple myeloma.Methods:During the time between October 2014 and May 2017,collected the Peripheral Blood from 35 newly diagnosed MM patients(22 males and 13 females;age range 49-67 years,median 60 years)and 40 healthy controls(19 males and 21 females;age range 45-70 years,median 57 years)which were all from the Provincial Hospital affiliated to Shandong University.Ten milliliters of venous peripheral blood were collected from all patients and control individuals.The blood was centrifuged and the serum was stored at-80℃.None of them had been transfused or treated by immunosuppressive therapy prior to sampling.Patients were accord with National Comprehensive Cancer Network and International Myeloma Working Group(NCCN/IMWG)criteria for the diagnosis ofmultiple myeloma in 2015.The immunoglobulin(Ig)class was 19 cases of IgG,11 cases of IgA,3 cases of kappa light chain and 2 cases of non-secretory type.According to the Durie-Salmon staging system,4 patients were MM disease stage I,14 patients were stage II,and 17 patients were disease stage III.IL-33 and IL-6 serum levels were measured in 35 MM patients and 40 healthy controls by the enzyme-linked immunosorbent assay(ELISA)and were studied in relation to disease stage and severity.Results:1.The serum IL-33 level in MM patients was significantly lower than that in the control group(P<0.001).The serum levels of IL-33 in stage III patients were significantly lower than those in stage Ⅰ and Ⅱ(P = 0.003 and P = 0.48,respectively).2.The serum IL-6 level in MM patients was significantly higher than that in the control group(P<0.001).The serum levels of IL-6 in stage III patients were significantly higher than those in stage I and stage Ⅱ(P = 0.007 and P = 0.004,respectively).3.There was no significant difference in serum IL-33 and IL-6 levels between stage I and II patients(P>0.05).4.The serum levels of IL-6 and IL-33 in patients with MM were negatively correlated(P<0.001,correlation coefficient =-0.740).Conclusion:We found that abnormal expression of IL-33 and IL-6 promotes the development and development of MM diseases.The monitoring of serum levels of IL-33 and IL-6 contributes to the diagnosis of disease,as well as to assess the activity of disease in MM patients.